ArticleArchives of surgery (Chicago, Ill. : 1960)2008
Importance of sentinel lymph node biopsy in patients with thin melanoma.
Article in Archives of surgery (Chicago, Ill. : 1960), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.European journal of nuclear medicine and molecular imaging · 2009Guideline
- Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.Annals of surgical oncology · 2014Trial
- A bibliometric analysis of sentinel lymph node biopsy in melanoma of the top 90 cited publications.Melanoma management · 2025Article
- Sentinel Lymph Node Biopsy in Melanoma: Overview and Updates.International journal of molecular sciences · 2025Review
- Review
- Melanoma: Staging and Follow-Up.Dermatology practical & conceptual · 2021Review
- Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.Current treatment options in oncology · 2021Review
- Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.JCO precision oncology · 2021Article
- Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost.Annals of surgical oncology · 2020Article
- Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis.Pathology oncology research : POR · 2020Article
- Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.JAMA dermatology · 2019Article
- Current management of regional lymph nodes in patients with melanoma.Journal of surgical oncology · 2019Review
- Melanoma & nuclear medicine: new insights & advances.Melanoma management · 2018Review
- Stratifying SLN incidence in intermediate thickness melanoma patients.American journal of surgery · 2018Article
- Analysis of sentinel node positivity in primary cutaneous melanoma: an 8-year single institution experience.Irish journal of medical science · 2017Article
- Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.JAMA dermatology · 2017Article
- Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis.Annals of surgical oncology · 2017Article
- Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy.Cancer medicine · 2016Article
- Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma.JAMA dermatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
hypothesisThe status of the sentinel node (SN) confers important prognostic information for patients with thin melanoma. DESIGN, SETTING, AND PATIENTS: We queried our melanoma database to identify patients undergoing sentinel lymph node biopsy for thin (< or =1.00-mm) cutaneous melanoma at a tertiary care cancer institute. Slides of tumor-positive SNs were reviewed by a melanoma pathologist to confirm nodal status and intranodal tumor burden, defined as isolated tumor cells, micrometastasis, or macrometastasis (< or =0.20, 0.21-2.00, or >2.00 mm, respectively). Nodal status was correlated with patient age and primary tumor depth (< or = 0.25, 0.26-0.50, 0.51-0.75, or 0.76-1.00 mm). Survival was determined by log-rank test.
main outcome measuresDisease-free and melanoma-specific survival.
resultsOf 1592 patients who underwent sentinel lymph node biopsy from 1991 to 2004, 631 (40%) had thin melanomas; 31 of the 631 patients (5%) had a tumor-positive SN. At a median follow-up of 57 months for the 631 patients, the mean (SD) 10-year rate of disease-free survival was 96% (1%) vs 54% (10%) for patients with tumor-negative vs tumor-positive SNs, respectively (P < .001); the mean (SD) 10-year rate of melanoma-specific survival was 98% (1%) vs 83% (8%), respectively (P < .001). Tumor-positive SNs were more common in patients aged 50 years and younger (P = .04). The SN status maintained importance on multivariate analysis for both disease-free survival (P < .001) and melanoma-specific survival (P < .001).
conclusionsThe status of the SN is significantly linked to survival in patients with thin melanoma. Therefore, sentinel lymph node biopsy should be considered to obtain complete prognostic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.